Lenalid 25 — Lenalidomide 25 mg

Indicated for:

• Multiple Myeloma (MM): In combination with Dexamethasone. Used in newly diagnosed patients and those who have received at least one prior therapy.
• Mantle Cell Lymphoma (MCL): For patients whose disease has relapsed or progressed.

Strength: 25 mg capsule.

Standard Cycle (28 Days):

• 📅 Days 1-21: Take one 25 mg capsule once daily.
• 📅 Days 22-28: Rest period (no medication).

⚠️ ADMINISTRATION:

• 💊 Swallow whole with water. Teratogenic hazard: Do not open or break capsules.
• Renal Alert: If Creatinine Clearance is < 60 mL/min, the dose must be reduced to 10 mg.

🚫 PREGNANCY WARNING (Category X):

Lenalidomide is structurally related to Thalidomide. It causes severe life-threatening birth defects. Strict pregnancy prevention programs must be followed by both men and women.

Also Contraindicated in:

• Severe hypersensitivity to the drug.
• Breastfeeding.

At 25 mg, toxicity monitoring is crucial:

• Severe Neutropenia/Thrombocytopenia: Grade 3-4 hematologic toxicity is common. Weekly blood counts are required for the first 8 weeks.
• Venous Thromboembolism: High risk of clots. Antithrombotic prophylaxis is mandatory.
• Fatigue and Rash.